#IMAB

2 months ago

Register for events: www.mobilize.us/indivisiblem...
More info: www.indivisiblemansfield.org/events/
Other events in our area: www.dosomethingsc.org/january-6-2026

#Attleboro #Easton #Foxboro #Mansfield #NorthAttleboro #Norton #Plainville #Seekonk #Sharon #Taunton #IMAB

4 4 0 0

@helpless2025.bsky.social

2 months ago

A reminder that food pantries still need donations 🍞
#Attleboro #Easton #Foxboro #Mansfield #NorthAttleboro #Norton #Plainville #Seekonk #Sharon #Taunton #IMAB

1 1 0 0

2 months ago

Stand Up for Democracy! · Indivisible Mansfield and Beyond Bring your friends and joins us for a peaceful and uplifting rally! We need to show that “ We the People” are not going away!

I'm attending Indivisible Mansfield and Beyond's event, “Stand Up for Democracy!” - sign up now to join me! #IMAB www.mobilize.us/indivisiblem...

0 0 0 0

3 months ago

IMAB Bridge Brigade 11/18
Believe the women and release the files!
#Attleboro #Easton #Foxboro #Mansfield #NorthAttleboro #Norton #Plainville #Seekonk #Sharon #Taunton #IMAB #BridgeBrigade #BelieveWomen

3 1 0 0

3 months ago

Schedules for food pantries in our area.
#Attleboro #Easton #Foxboro #Mansfield #NorthAttleboro #Norton #Plainville #Seekonk #Sharon #Taunton
#FoodPantry #IMAB

0 0 0 0

4 months ago

Join us for our monthly meeting on Saturday, November 15 at 9:00 AM at Murray UU in Attleboro.
#Attleboro #NorthAttleboro #Easton #Foxboro #Mansfield #Norton #Plainville #Sharon #Taunton #FightFacism #IMAB

2 1 0 0

4 months ago

Places to donate food and funds to feed families in our communities. #Attleboro #NorthAttleboro #Easton #Foxboro #Mansfield #Norton #Plainville #Sharon #Taunton #SNAP #FoodPantry #Donate #IMAB

5 2 0 0

4 months ago

Honor Vets
Resist Fascism
#IMAB
#VisibilityBrigade
#BridgeBrigade
@indivisible.org
@hcrichardson.bsky.social

0 0 0 0

4 months ago

End the GOP shutdown!
#IMAB
#bridgebrigade
#VisibilityBrigade

0 0 0 0

@helpless2025.bsky.social

4 months ago

End the GOP Shutdown!
Fund healthcare and SNAP
#IMAB

0 0 0 0

4 months ago

No Kings Rally-Train to Boston! · Indivisible Mansfield and Beyond Get pumped for NO KINGS in Boston! We'll rally with our NO KINGS signs for an hour before getting on the train together!

I'm attending Indivisible Mansfield and Beyond's event, “No Kings Rally-Train to Boston!” - sign up now to join me! #IMAB www.mobilize.us/indivisiblem...

0 0 0 0

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences I-Mab (NASDAQ: IMAB) announced a strategic transformation to become a global biotech platform renamed NovaBridge Biosciences, with a planned Hong Kong IPO for a dual listing on NASDAQ and HKEX. Shareholder approval for the name change is expected at an EGM on October 24, 2025. The company will form a subsidiary, Visara, to acquire VIS-101 (also ASKG712), a VEGF-A/ANG2 bifunctional biologic completing Phase 2 and anticipated to be Phase 3-ready in 2026. Visara will launch with an approximately $37M capital infusion; Transactions are cross-conditioned and expected to close later this month. Kyler Lei is appointed CFO effective Oct 16, 2025.

4 months ago

#IMAB I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

www.stocktitan.net/news/IMAB/i-mab-announce...

0 0 0 0

I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update I-Mab (NASDAQ: IMAB) reported Q2 2025 financial results and business updates, highlighting significant progress in its oncology pipeline. The company's lead drug givastomig showed promising Phase 1b results with an 83% objective response rate in combination with immunochemotherapy for first-line gastric cancers.I-Mab strengthened its financial position through an underwritten offering raising $61.2 million, resulting in a pro-forma cash balance of $226.8 million as of June 30, 2025. This funding is expected to sustain operations through Q4 2028. The company reported reduced R&D expenses of $3.3 million for Q2 2025, down from $5.2 million in Q2 2024, and a net loss of $5.5 million for Q2 2025.Key upcoming milestones include topline data from givastomig's Phase 1b dose expansion study expected in Q1 2026. The company also acquired Bridge Health, strengthening its intellectual property portfolio for givastomig.

6 months ago

#IMAB I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/IMAB/i-mab-reports-...

0 0 0 0

I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers I-Mab (NASDAQ: IMAB) has completed enrollment in its Phase 1b dose expansion study for givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, combined with nivolumab and mFOLFOX6 for first-line treatment of CLDN18.2-positive gastric cancers. The study enrolled 40 patients across two doses (8 mg/kg and 12 mg/kg) in the U.S.Earlier dose escalation data presented at ESMO GI 2025 showed promising results with an 83% objective response rate (10/12 patients) at the selected doses. The treatment demonstrated rapid and durable responses with favorable safety profiles. Topline results from the expansion study are expected in Q1 2026.

7 months ago

#IMAB I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers

www.stocktitan.net/news/IMAB/i-mab-complete...

0 0 0 0

I-Mab Secures $65M Backing from Top Investors to Advance Cancer Immunotherapy Trial Biotech firm prices $1.95 ADS offering with Everest Medicines, Janus Henderson backing. Funds target Phase 2 trial of novel cancer immunotherapy. Get details.

7 months ago

#IMAB I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares

www.stocktitan.net/news/IMAB/i-mab-announce...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

7 months ago

Leading Indicators, Monday July 28, 2025 – Crystal Equity Research

Small-cap stocks in new downtrend with AROON Oscillator, Mon Jul 28th - #AERT #BNTC #CASS #DMRC #EM #FMBH #IMAB #MPB #NRIM #RGP #XYF #UMH #SITC #OOMA #IFN #GEL #FVRR #CHPT #BFS #AGM #SEGG #WALD #ZJK - More: crystalequityresearch.com/ieading-indi... - #smallcap

0 0 0 0

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health I-Mab (NASDAQ: IMAB) has announced the acquisition of Bridge Health Biotech in a strategic move to strengthen its intellectual property portfolio for givastomig, a CLDN18.2 x 4-1BB bispecific antibody. The transaction provides I-Mab with rights to bispecific and multi-specific applications of the CLDN18.2 parental antibody.The deal includes an upfront payment of $1.8 million, non-contingent payments of $1.2 million through 2027, and potential milestone payments up to $3.875 million. The acquisition eliminates future royalty obligations and reduces milestone payments for givastomig.Recent Phase 1b dose escalation data showed promising results with an 83% objective response rate in selected doses for expansion cohorts. The company expects to present topline results from the Phase 1b dose expansion combination study in Q1 2026.

7 months ago

#IMAB I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

www.stocktitan.net/news/IMAB/i-mab-strength...

0 0 0 0

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Company to host investor event on Tuesday, July 8 th ROCKVILLE, Md., July 02,

8 months ago

#IMAB I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

www.stocktitan.net/news/IMAB/i-mab-presents...

0 0 0 0

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research I-Mab (NASDAQ: IMAB) announced the publication of promising clinical data for givastomig, their bispecific Claudin 18.2 x 4-1BB antibody, in Clinical Cancer Research. The Phase 1 monotherapy study demonstrated an objective response rate (ORR) of 18% in heavily pretreated Claudin 18.2-positive gastric cancer patients.Key findings from the 75-patient study include:7 confirmed partial responses in 43 evaluable patients with CLDN18.2-positive advanced gastric cancerDisease control rate (DCR) of 49% (21/43 patients)Median duration of response of 9.4 monthsActivity observed across Claudin 18.2 expression levels (11% to 100%)No dose-limiting toxicity reported up to 15 mg/kg Q2W and 18 mg/kg Q3WThe company will present additional combination therapy data with nivolumab plus mFOLFOX6 at the upcoming ESMO GI Cancers Congress 2025 on July 2nd in Barcelona.

8 months ago

#IMAB I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

www.stocktitan.net/news/IMAB/i-mab-announce...

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

8 months ago

#IMAB Update
#IMabBiopharma reports encouraging Phase 1b data for givastomig in first-line metastatic gastric cancer. The therapy showed a 71% response rate overall and 83% in key dose groups.
prismmarketview.com/i-mab-report...

0 0 0 0